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It is with great delight that I welcome you to this, our 13th Annual Pancreatic 
Cancer and Related Diseases Patient Symposium. This is our most special 
event of the year. It is with much anticipation that we plan this event. We 
welcome back many of our patients, friends, and families. We also welcome 
those who are new to Jefferson, and to this symposium. 
I hope that you enjoy the contents of this extensive publication, which has 
been supervised by our superb Sidney Kimmel Medical College of Thomas 
Jefferson University medical students, some of whom may be pancreas 
surgeons some day! 
In this publication you will find some fascinating stories, interviews, research 
updates, and contributions. We are proud to be leaders in the field of 
pancreatic and related cancer research, not only clinical research but bench 
research, translational research, and epidemiological research. We hope that 
you find this day exciting, invigorating, educational, and tasty (we do provide 
free breakfast and lunch). 
Thank you for celebrating Pancreatic Cancer Awareness Month with us, and 
for joining us here at Jefferson as we continue to make an impact in our 
fields of research and clinical care delivery. There are many exciting things 
going on here at Jefferson Health. It is terrific to see you join us in the fight. 
Charles J. Yeo, MD, FACS
Samuel D. Gross Professor and Chairman 
Department of Surgery







CONCERNING RESEARCH IN GENERAL
Q: Was it always your intent to become a 
researcher or did something along the way inspire 
you to change course?  
A: It was really just the next step. I was on the faculty 
at the Johns Hopkins School of Nursing and the 
Dean at that time was Martha Hill who encouraged 
the faculty to pursue advanced degrees. I chose a 
PhD in public health, as I was particularly interested 
in cancer, and the epidemiology of cancer. I was able 
to complete my education at the Johns Hopkins 
Bloomberg School of Public Health while a faculty 
member and the mother of two small children.  
Q: You’ve written a paper about mentorship and 
mentors. Can you describe your most influential 
mentors?  
A: One of my most important mentors has been my 
husband, Dr. Charles Yeo, who has encouraged me 
all along the way and even tutored me in biostatistics. 
I could not have completed a dissertation without 
his support and that of our family. Charlie’s work 
with pancreas cancer patients was very interesting 
to me, and led me to get involved in the clinical 
care of pancreatic cancer patients and research in 
the area.  
Q: What qualities did your mentors have that 
helped you grow in your career?  
A: Being supportive. Letting you know that it wasn’t 
necessarily about how smart you are, but how hard 
you were willing to work and persevere in what 
you want. I also had a great mentor in the Hopkins 
School of Nursing, Dr.  Candis Morrison, who was 
a PhD-prepared oncology nurse practitioner. We 
worked together on the hematologic malignancy 
service and she had a “you can do this” attitude that 
really helped me believe in myself.  
Q: Do you have advice for identifying a good 
mentor?  
A: It’s really important for young people to have 
a mentor that they like and one in whose work 
they’re interested. We all have informal mentors 
in our lives, but the professional ones should be 
formalized and that means having ground rules. 
It should be clear what is expected on both sides 
Dr. Theresa Yeo received her BSN from Cornell University in 1976, an MSN from the University of Virginia, and MPH and PhD 
degrees in public health from the Johns Hopkins University, Bloomberg School of Public Health.  
She spent 30 years of her career in Baltimore, MD, as a Johns Hopkins nurse, Johns Hopkins School of Nursing faculty member, 
and researcher before coming to Jefferson with her husband, Dr. Charles J. Yeo, Samuel D. Gross Professor of Surgery. 
Since her 2005 arrival in Philadelphia, she has served as an Associate Professor in the Jefferson College of Nursing, Program 
Director for Oncology Nursing, Co-Director of the Jefferson Pancreas Tumor Registry, and a nurse practitioner in the Jefferson 
Pancreas, Biliary and Related Cancer Center.  Dr. Theresa Yeo continues to teach nursing and medical students, mentor 
doctoral level students, conduct investigator-initiated research focused on symptom management and quality of life issues 
in cancer patients, and publish and disseminate research findings at national and international symposia. She has received 
federal, societal, intramural, and private research funding.
Dr. Yeo has published 53 peer-reviewed articles and abstracts and 16 book chapters, and co-edited one cookbook.  She is an 
Associate Editor of the Journal of Pancreatic Cancer and serves on numerous peer-review editorial boards, including Annals 
of Surgery, JOGS, CJON, the Journal for Nurse Practitioners, Oncology Nursing Form, and the Journal of Allied Health. She 
was an expert reviewer for the 2018 Kaiser Permanente Research Affiliates Evidence-based Practice Center Project: “Screening 
for Pancreatic Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force” (Prepared for the Agency for 
Healthcare Research and Quality). 
In 2017, she received the Distinguished Alumni Award from Cornell University in recognition of her contributions to the field 
of professional nursing.
PERSPECTIVE
An Interview with Dr. Theresa Yeo, Co-Director of the 
Jefferson Pancreas Tumor Registry (JPTR)
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of that equation. A mentor has responsibilities and 
duties and the mentee has obligations and duties as 
well. Sometimes you have to try out a few mentors 
before you find the one that is going to work.
CONCERNING PANCREATIC CANCER
Q: What drew you to pancreatic cancer research 
specifically?
A: My husband’s career! In the early 1990s the 
Johns Hopkins Department of Surgery applied 
for and received the first NIH SPORE grant to 
study pancreas cancer with Dr. Charles Yeo as the 
Principal Investigator. This stimulated a great deal 
of research in many related areas. At that time I 
was involved with the Hopkins National Familial 
Tumor Registry and I was able to use that database 
to develop a dissertation thesis, which evaluated 
environmental and occupational risk factors for 
pancreas cancer in a cohort of familial and sporadic 
pancreas cancer patients.
Q: What are the goals of the Jefferson Pancreatic 
Tumor Registry and what need did it fill that was 
previously unmet?  
A: In 2005, when Dr. Yeo and I came to TJUH, there 
was not a pancreas tumor registry. We formed 
an Advisory Board and in 2008 the IRB approved 
the protocol for the JPTR and we began enrolling 
patients. Dr. Harish Lavu had recently arrived on 
the faculty from Indiana University and UCLA and 
served as the first Director of the Registry. Just this 
summer we published a descriptive review of the first 
10 years of the Registry in the Journal of Pancreatic 
Cancer.1 The purpose of the Registry, a longitudinal, 
epidemiological study, is to collect information on 
hereditary conditions, family history of cancers, 
and occupations and environmental exposures to 
known human carcinogens. In conjunction with 
our Jefferson tumor-banking study, we are also 
able to use DNA tumor samples and family history 
to make decisions about personalized and precision 
therapy. Lastly, we sought to start a high-risk, non-
affected family member surveillance screening 
program. Through our annual follow-up surveys, a 
community of survivors and their relatives has been 
created. It is precious data and we recognize what a 
privilege it is to collect these data that describe the 
lived experience of people with pancreas cancer 
and other related conditions.
Q: Have there been any surprising findings so 
far? 
A: There has been much interesting scientific 
research from the lab of Dr. Jonathan Brody, 
Director of Research in the Department of Surgery. 
For example, we have found polymorphisms in a 
tumor suppressor gene called WEE1 - SNP indels 
in an RNA binding site. Individuals who carry one 
specific allele enrichment pattern are more likely 
to have first-degree relatives with Lynch-type 
cancers.  
Q: Is there anything being worked on now in the 
field that may dramatically change the detection 
or treatment of the disease in the near future?  
A: The major treatment advances are going to 
be made on the molecular side. Finding out the 
molecular mutations and alterations in these 
various tumors and developing chemotherapies 
that can target those actionable mutations. Early 
detection is critical. We encourage all persons with 
a family history of pancreas cancer to be under 
surveillance by an experienced GI physician who is 
familiar with pancreas cancer.
CONCERNING YOUR RESEARCH INTERESTS
Q: Could you describe some of your efforts 
regarding quality of life in patients with cancer?  
A: This has been an interest of mine for a number 
of years. When you work with a cancer population 
with high rates of morbidity and mortality you think 
about their quality of life and what interventions may 
improve it. In 2009, we conducted a randomized-
controlled trial in post-operative individuals with 
pancreas cancer using a home walking program 
as the intervention. We randomized post-Whipple 
patients to either the home walking program or 
to “usual care”, meaning that they could perform 
any activity that they wanted. We assessed fatigue 
(the number one presenting symptom of pancreas 
cancer and also the most persistent symptom 
after treatment). Published literature suggested 
that walking and exercising helped decrease the 
symptom burden in cancer patients and we wanted 
to test that theory. We designed and carried out the 
study from 2009 to 2011. One hundred and one 
patients participated. We found that the group that 
walked and/or  exercised had less  fatigue, weight 
loss, anxiety, and depression.2 Based on those 
findings, we now routinely give our post-surgery 
patients a walking prescription to follow at home.
Q: What has motivated you to devote time to 
researching topics like exercise and relaxation in 
GSR November 2018
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the cancer patient population? 
A: There is such a need for this type of research. 
Cancer patients deal with difficult situations and 
multiple issues. You think to yourself: “What can I 
do as a healthcare professional to find ways to help 
people?” Exercise has been important in my life for 
dealing with stress and improving my own quality 
of life. We have a very motivated team of surgeons, 
oncologists, nurses, and nurse practitioners 
who are interested in helping change lives and 
conducting research.
Q: What research project do you look back and 
feel most proud of?  
A: I was very proud of designing and completing 
my dissertation study. The walking study was also a 
well-done study. It was an amazing experience to 
connect with the patients, to talk with them every 
month and to read in their log sheets how they 
were doing and what problems they were having. 
I think it really helped people.  
CONCERNING NURSING
Q: Has your background in nursing helped you in 
your career in research?  
A: Absolutely. I am first and foremost a nurse. I 
went to the Cornell University School of Nursing. It 
was an incredible, exceptional school. The nursing 
education that I received has held me in great stead 
for all of my career. In everything I do now, I’m still 
a nurse at heart.
Q: Is there anything you miss about clinical 
nursing that you don’t get from your current 
position?  
A: My current position is the perfect blend of being 
a clinical nurse practitioner and a researcher. I see 
patients in office hours, at the Jefferson Pancreas, 
Biliary and Related Cancer Center as part of our 
team every week. It is my favorite part of the 
position! 
Q: The United States is projected to face an 
increasing shortage of physicians in the coming 
years. You’ve written that you think this is an area 
in which nurse practitioners (NPs) can play a larger 
role. Do you think that the medical profession will 
welcome a growing parity amongst physicians 
Dr. Theresa Yeo hosting the Jefferson Pancreas Tumor Registry information table  
at the 2016 Pancreatic Cancer and Related Diseases Patient Symposium
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and NPs, or do you think there will be resistance? 
A: The role of the nurse practitioner can be both 
complementary to medicine and can be integrated 
into medicine. In my own career, I’ve always felt 
welcomed and valued as part of the team. I think 
that nurse practitioners can definitely play a 
larger role in health care, particularly in areas of 
need, such as rural areas where there are very few 
physicians. Physician Assistants have a growing 
role in this area as well. There is some resistance 
from the AMA, to nurse practitioners, but there are 
plenty of patients and areas in desperate need of 
health care providers to go around.
Q: Outside of increasing the role of NPs in primary 
care, what are the other areas of clinical medicine 
that you think would benefit from an increased 
presence of NPs?
A: There is a role for nurse practitioners in both 
inpatient and outpatient settings. Just about any 
setting is improved by having a nurse practitioner 
as part of the staff! The key to being a successful 
nurse practitioner, I would say, is to know when to 
ask for help, know what you don’t know, and never 
pretend to know something you don’t.
Q: You’ve written about the role of advanced 
practice nurses in culturally competent care in the 
field of oncology. Can you discuss that role and 
why advanced practice nurses are uniquely suited 
to overcoming or bridging cultural boundaries?  
A: The demographics and cultural backgrounds 
of our society are changing. We need a workforce 
that can relate to people from many different 
backgrounds. Cancer is a much feared disease 
and a time when patients and their loved ones 
are facing some of the most difficult decisions of 
their lives.  Having a health care provider who is 
culturally aware and sensitive is much appreciated 
by patients. Jefferson had one of the only programs 
in the country that was focused on preparing 
culturally competent advance practice nurses. 
Q: What strategies do you think could foster a 
greater respect between physicians and NPs?  
A: Many schools have started interdisciplinary 
programs in which nursing, pharmacy, physical 
therapy, and medical students work together on 
joint projects. I’ve been involved with some of these 
projects here at Jefferson as a faculty member. 
Students often know very little about each other’s 
Drs. Charles and Theresa Yeo
Team Jefferson poses for a 
picture before the annual 




role on the health care team, how their roles 
overlap, and how they could collaborate. I see that 
there is a growing awareness and acceptance of 
other peoples’ roles and a greater collegiality as a 
result of these initiatives.
Q: You’ve looked into incivility in the healthcare 
work place. What tactics do you think can cut 
down on instances of incivility?  
A: Incivility is a growing problem in our society. 
Each person has to take responsibility for their 
own behavior. There are a number of very simple 
tactics that can be used: count to ten before 
speaking, walk away from a difficult email and think 
it through before answering, listen more, talk less, 
and be respectful of others’ opinions. When you 
have a problem, rather than letting it escalate, go 
and speak privately with whomever you are having 
the problem. Consider: “Is this their problem or is 
this my problem?” Ask yourself, “Who can I really 
change?” You can only change yourself. And that 
goes back to taking responsibility for your behavior 
and being more responsible about how you act in 
the workplace.
Q: How have you personally dealt with uncivil 
behavior both as a nurse and as a research 
scientist?  
A: First let me say I’ve been both the perpetrator 
of incivility and the object of incivility. No one is 
perfect. Remember that you are a professional. 
Sometimes it requires you to walk away for a 
while, to sleep on it, and to not push the “send” 
button. One of the lessons I have learned in my 
career is to not overreact; not every perceived or 
real slight needs to be addressed. Choose your 
battles carefully and try to be rational, calm, and 
diplomatic in your approach.     
CONCERNING COOKING
Q: Your name is on a cookbook of Philadelphia’s 
favorite recipes. Do you like to cook?  
A: I was honored to be president of the Jefferson 
Women’s Board for three years. When I was 
president, the major project we undertook for 
fundraising was to compile a cookbook about 
Philadelphia cuisine. The cookbook featured 
Jefferson medical history and Philadelphia’s 
culinary past. All of the recipes were submitted by 
members of the Jefferson community and they 
were all tested. My family tasted many of these 
recipes! It was a successful project and great fun.
REFERENCES
1. Yeo TP, Lavu H, Nevler A, et al. Precious Data: 
Interim Report from the Jefferson Pancreas Tumor 
Registry. Journal of Pancreatic Cancer. 2018;4(1):17-24. 
doi:10.1089/pancan.2018.0004
2. Yeo TP, Burrell SA, Sauter PK, et al. A progressive 
postresection walking program significantly improves 
fatigue and health-related quality of life in pancreas 
and periampullary cancer patients. J Am Coll Surg. 
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Dr. Neal McCall graduated from Sidney Kimmel 
Medical College (SKMC) in 2018, and is now in his 
PGY-1 year at Emory University for his residency 
in Radiation Oncology. Dr. McCall first became 
interested in pancreatic cancer research after 
listening to Dr. Charles Yeo, Samuel D. Gross 
Professor and Chair of Surgery at Thomas Jefferson 
University, give a talk on pancreatic cancer during 
his first year of medical school. He reached out 
to express his interest and was introduced to Dr. 
Harish Lavu. 
Dr. Lavu served as a crucial mentor for the 
formative phase of Dr. McCall’s research career. Dr. 
McCall’s foundations in clinical research are due 
to Dr. Lavu’s strong influence and guidance, and 
he is tremendously grateful to Dr. Lavu for this. Dr. 
Lavu not only provided the direction and oversight 
to build a research skill-set, but he also provided 
enough space for Dr. McCall to grow and overcome 
obstacles on his own. This balance led to invaluable 
personal growth to which Dr. McCall attributes his 
early career success.
Dr. McCall’s first project with Dr. Lavu, titled “Leakage 
of an Invagination Pancreaticojejunostomy May 
Have an Influence on Mortality,” provided an 
archetype of how he would conduct and write 
his future projects.1 This experience played an 
important role in allowing Dr. McCall to participate 
in and contribute to subsequent projects. His time 
with Dr. Lavu has developed his skills and given him 
a strong foundation in clinical research. Dr. McCall 
was involved in several research projects as a 
medical student, and recently several of his papers 
were published.2,3 
Dr. McCall’s interests and research led him towards 
oncology, and he dedicated much of his time to 
learning and exposing himself to essential aspects 
of pancreatic cancer and the surgeries involved. 
For Dr. McCall, using his anatomy knowledge and 
appreciating the complexities of surgery was a 
cerebral experience, and it attracted him from the 
beginning. As medical school progressed and he 
learned more about the care of pancreatic cancer 
patients, Dr. McCall stumbled upon the world of 
radiation oncology.
As Dr. McCall delved deeper into radiation oncology, 
his interest in the field grew, and he seriously began 
considering it as a prospective career path. He 
was drawn to the mix of patients, the variation in 
treatment plans, the courses of the diseases, and 
the option to cure or palliate. In Dr. McCall’s own 
words, “You think about how you’re planning it; you 
think about the dose, anatomic relationships, data 
collection, and collaborating with other people. 
I love those aspects of it, and I love that it’s in a 
relatively low-stress environment. That’s how I 
thrived on it.”  
When asked if there was a pivotal decision point 
in his career choice, he had to weigh how the 
different aspects of training and his intellectual 
interests aligned. Foremost, his passion is in 
oncology, and he was sure that he wanted to work 
with that patient population and be part of planning 
their care. Certainly, the training that medicine and 
surgery provide are quintessential for all paths in 
medicine, and either would have provided a robust 
clinical foundation in treating all patients. However, 
Dr. McCall recalled the main deciding factor to 
pursue radiation oncology to be the connection 
between planning for care and anatomy. “I like 
thinking anatomically, and there’s something about 
thinking about anatomy that’s really missing for me 
A PGY-1’s Perspective: 
Conducting Pancreatic Cancer Research as a Medical Student 
BY: KEVIN XIE, CLASS OF 2021
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in medical oncology,” said Dr. McCall.  “I love the 
science and pharmacology of medical oncology,” 
he continued, “but the reality is that you are actually 
involved in those things both as a radiation and 
surgical oncologist too. You’re just not the one 
prescribing them. Regarding research trials, you still 
have to see the patients and understand the science 
behind it. That’s certainly not missing in surgical 
and radiation oncology.”
Dr. McCall knew from the start that oncology was 
his passion, and a career in Radiation Oncology 
was the right decision for him. The invaluable 
experience he had working with Dr. Lavu in 
pancreatic surgery provides him with an edge when 
it comes to understanding the intricacies of patients 
that are surgical candidates. Dr. McCall emphasized 
that the planning and decision making involved, 
coordination with other disciplines for neoadjuvant 
care, and post-operative care are all things he 
learned under Dr. Lavu’s tutelage, and these lessons 
will guide his perspective on pancreatic cancer 
treatment in the future. Although Dr. McCall ended 
up not choosing Surgical Oncology as a career, he 
and Dr. Lavu continue to collaborate on research 
endeavors.  
Dr. McCall’s impressive research accomplishments 
were an essential aspect of his residency applications, 
and lent him a competitive edge. His contribution to 
the WARP (Whipple Accelerated Recovery Pathway) 
trial was an important component of his application 
that captured the attention of his interviewers. 
Since many students do not have the opportunity 
to contribute meaningfully to a randomized clinical 
trial like WARP, the residency programs emphasized 
this experience in their interviews. Dr. McCall 
recounts that this clinical experience made him 
stand out amongst his fellow applicants. “Radiation 
oncology is an academic field. Everyone who is 
working in academics especially is passionate 
about research. It is quite a small field, and because 
of that, research is the most important thing, and 
it’s hands down the thing that came up the most.”
He also attributes much of his research and interview 
success to his work with Dr. Lavu, going on to say, 
“I don’t think I would have been as successful in 
medical school. I think that building a strong clinical 
research background makes you a better doctor 
no matter what you do because you’re just able to 
interpret evidence better than colleagues who don’t 
have that experience. And you’re able to actually 
apply it to patients who are right in front of you. So 
I don’t think I would have been as successful during 
my M3 and M4 years, or even now, just because, in 
my opinion, that experience is really foundational 
for understanding how to practice medicine as 
a whole. Whether you’re in surgery, medicine, or 
radiation oncology, that’s a vital skill to have, and 
my experience with Dr. Lavu is what developed that 
skill overall.” 
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CONCERNING RESEARCH IN GENERAL
Q: When did you first develop an interest in 
research? Can you describe your general track to 
becoming a PhD? Did you make this decision in 
high school or undergraduate?
A: I actually attended my undergraduate institution 
(Skidmore University) on a music scholarship. I was 
a percussionist and I found my passion for music 
when I was diagnosed with juvenile rheumatoid 
arthritis as a child. I had been a soccer player until 
the age of 9 when I developed JRA, which left 
me confined to a bed for many weeks during the 
summer, not knowing whether or not I would be able 
to walk freely again. Luckily it was an acute episode 
over one summer and I regained full function, but 
it was during that time that my mom’s friend, Linda, 
bought me drum sticks and drum lessons. For the 
rest of my schooling, I played percussion — I played 
vibraphone, marimba, and drum set.
Arriving in NY from a small town in Maryland, I 
appreciated pretty quickly how competitive a career 
in music was, and after doing an internship at the 
NIH one summer, I realized that many of the things 
I loved about music, like being creative, translated 
into research. I did think about a career as an MD, 
but with so many things in medicine that we do 
not have a cure for, I got really interested in cancer 
research and trying to help people in this capacity.
I did my PhD at Hopkins, which was mostly 
centered around cancer and molecular biology. 
For my fellowship, I worked for the researcher who 
described more mutations in pancreatic cancer 
than anyone in the world. It was through him that 
I found myself focused in on pancreatic cancer, 
and in fact I was part of the same team at Hopkins 
that included Dr. Yeo. Dr. Yeo came to Jefferson in 
INTERVIEW
 
Jonathan Brody, PhD 
Pancreatic Cancer Specialist 
BY: CARRIE DIANNE WALSH, CLASS OF 2020
Dr. Brody is the Director of Surgical Research and Co-director of the Jefferson Pancreas, Biliary and Related Cancer Center. 
He is also the current Chair, Cancer Research Program (PRCRP), Department of Defense (Army) in Washington, D.C. The main 
focus of Dr. Brody’s laboratory is to understand the molecular aspects of pancreatic cancer cells and find novel therapeutic 
strategies for pancreatic cancer patients.
During his over ten years of training at Johns Hopkins University, Dr. Brody began exploring drug-target interactions. Utilizing 
diverse molecular biology techniques that include DNA sequencing, gene knockout and silencing assays, and drug sensitivity 
assays, Dr. Brody has published extensively on aspects of chemotherapeutics, namely gemcitabine, 5-fluorouracil, and 
platinum-based agents. Part of this work includes his special interest in targeting cancer cells with defects in the BRCA2/
Fanconi anemia DNA repair pathway.
His work also includes advancement in the basic DNA detection technique of DNA electrophoresis, by discovering new 
and better alternatives to tris-based buffers, such as lithium-based buffers, that can separate DNA in a fraction of the time 
compared to conventionally used conductive media. In relation to gene regulation and mRNA stability, Dr. Brody aided in 
cloning members of the pp32 gene family over a decade ago. Members of this family, pp32 and APRIL, have been shown 
previously to be ligands and functionally interact with the RNA binding protein, HuR. Currently, Dr. Brody’s work focuses on 
how HuR biology is involved in pancreatic tumorigenesis as well as cancer cell survival. His laboratory is also interested in 
how HuR expression levels and protein subcellular localization affects treatment of pancreatic cancer. Recently, the group 
published work showing that HuR subcellular localization can be potentially a valuable predictive marker for the standard of 
care with therapies for this disease. His laboratory’s work is now primarily focused on HuR biology as it relates to the clinical 
management of cancer, including identifying clinically relevant HuR targets.
Finally, Dr. Brody is continuing his research in studying drug-target relationships as he is the principal investigator on a 1 
million dollar grant (supported by the Pancreatic Cancer Action Network) that supports an unprecedented clinical trial testing 
a molecular based, personalized approach to treating pancreatic cancer patients.
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2005, and started the pancreatic 
research program at Thomas 
Jefferson University Hospital. 
It was about a year later that he 
called me up and invited me to 
join his team.
Q: How did you decide between 
pursuing an MD vs. a PhD degree 
(or both)? 
A: I played with the idea of doing 
an MD/PhD program, but I fell in 
love with being in a lab and doing 
research. I guess that I felt that 
it would be the best use of my 
talents, and the best way that I 
could help people. 
I have so much admiration for 
clinicians who treat patients, and in 
fact I did a bunch of volunteering 
at various clinics during undergrad, 
but I realized that it was very hard for me to treat a 
patient and then go home and live my life without 
becoming emotionally invested.
I enjoy being around people and mentoring 
students, but I wanted to push forward in our 
understanding of an untreatable disease, with the 
hope that we can eventually find a cure for our 
future patients. 
Q: Who was one of your most influential mentors? 
What lessons did you take from this experience, 
and how do you use these lessons when it comes 
to mentoring other students?
A: I would say that my two most influential mentors 
were my drum teacher, and Scott Kern who was my 
postdoc fellow at Hopkins. Dr. Kern was also part 
of Dr. Yeo’s group. I think that they both taught me 
that in order to best utilize my talents, to be creative 
and to perform at my best, I needed to be extremely 
prepared. In science, this means becoming as 
knowledgeable about a subject as possible before 
you work on it. 
They also taught me the importance of thinking 
outside of the box, and how this method of thinking 
helps cultivate creativity both in the arts and in 
science. By constantly thinking in the box, you are 
not going to be able to make a difference. In fact, 
I wrote an article with my mentor from Hopkins 
on herd mentality in science, especially in the 
biomedical sciences, and how the concept of group 
thought and herd mentality can be a bad thing for 
scientific progress. 
And finally, my parents are my ultimate mentors, 
as they are true academics and teachers and they 
taught me the principles of: 1) never stop searching 
for the truth, and 2) teaching is the most important 
thing you can do to help society.
Q: I read that you joined Jefferson in 2006. How is 
your experience at Jefferson the same or different 
from your time at Johns Hopkins?
A: That is a difficult question to answer because I 
did all my training at Hopkins, which meant that 
I was fulfilling a different role there to the one I 
currently hold at Jefferson. I think that Hopkins is 
a great place to train, but I also think that whatever 
training program or institution you attend, what 
really makes the difference is the people you are 
with, and your mentors/professors. 
I think that the core research faculty at Jefferson are 
extremely strong, and in some areas, even stronger 
than those at Hopkins. Additionally, people here at 
Jefferson are extremely collaborative — as I also 
found them to be at Hopkins. In fact, many people 
say that Hopkins is very competitive, but I always 
found everyone to be extremely cooperative at 
both universities.
One of the similarities between the two institutions 
Dr. Brody with members of the laboratory at PurpleStride 
Philadelphia, hosted by the Pancreatic Cancer Action Network. 
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is that both Jefferson and Hopkins are diverse 
enough that if we find something new and 
interesting in the lab, I can find someone within 
each of the institutions who is an expert. The other 
similarity is mostly because of Dr. Yeo. Dr. Yeo has 
developed both hospitals into high-volume centers 
for pancreatic surgery, which means that we have a 
large source of specimens to draw from, along with 
a database and important registry. 
The multidisciplinary approach of both Jefferson 
and Hopkins, which brings researchers and clinicians 
together to try and make a difference — not just 
patient to patient, but globally — is extremely 
important. 
Q: I read that you have over 120 publications in 
the peer-reviewed literature. What advice would 
you give to students, residents, and junior faculty 
members who are excited about pursuing a similar 
career in research? Would you have different 
advice for MDs vs. PhDs?
A: You have to pursue what is exciting for you. I 
also think that it is important to like the people you 
work for. One of my old mentors from Hopkins, Don 
Coffey, used to say, “Whatever you think about in 
the shower or when driving your car into work, that 
is what you are going to end up being good at, and 
that is what you should invest your time in.”
For students, residents, and senior faculty, it is 
important to pair up with someone who has 
experience. If you see that someone has a good 
track record of publishing papers, they ask good 
questions, and they are a good mentor - someone 
like Dr. Harish Lavu - then connect with them and 
get their guidance. You need to find good mentors, 
but having said that, I do think that it is hard to 
find people who actually care about the process/
question and mentoring and are not just out for 
people to give them a paper. As a mentor, you have 
to roll up your sleeves and get to it because it is a 
two-way street. I am a firm believer that whatever 
time I put into students and residents will end up 
being an investment in the overall success of the lab 
and the work.  It is also very fulfilling to see students 
and residents get excited about a project and follow 
through in the pursuit of trying to answer a good 
scientific research question. 
The only thing I would say that is different for 
MDs vs. PhDs, is that you need to personalize 
your educational experience depending on what 
program you are studying in.
The accountability of the student is also important. 
I tell students all the time, “It is ok to knock on my 
door or email me.” I want that accountability in a 
student.
Q: What advice would you give to junior MDs that 
are looking to become affiliated with PhDs for 
basic and translational research, similar to your 
relationship with Dr. Yeo? How did you go about 
picking the MDs/Institution to become affiliated 
with?
A: I think it is like any relationship, it does not have 
to be perfect, but there has to good chemistry, 
and you have to have mutual appreciation for one 
another. For instance, Dr. Yeo, who for me, is the 
epitome of the perfect surgeon — dedicated, on top 
of his game, and someone who expects the best 
from everyone — respects and appreciates what I 
do. 
Dr. Yeo, Dr. Lavu, and I are a team with a common 
goal to make a difference for this disease, and if 
we can accomplish that, then the team wins. So, to 
answer your question, I believe that you have to find 
people with the same mission and values as you, 
and those that respect what each member of the 
team can bring to the table.
Q: Was there a moment or project that made 
you decide to dedicate your work to focusing on 
pancreatic cancer?
A: It was really my experiences at Hopkins that 
inspired me to dedicate my work to pancreatic 
cancer. This may sound very philosophical, but 
pancreatic cancer is one of those diseases that the 
more we know the less we know. Even though we 
know a lot, there is also a lot that we don’t know, 
and for me, the challenge of that is very exciting. 
From a researcher’s perspective, the expectations 
are high, and although I don’t like these numbers 
for our patients, I’d rather dedicate my work to 
something where people are given a 9% chance 
to live five years vs. a disease like prostate cancer 
where patients are given a 90% chance to live five 
years. 
Pancreatic cancer is a disease that is under-
recognized and under-funded. There are not a lot 
of advocates out there because patients diagnosed 
with the disease usually get angry and then 
unfortunately pass away very quickly because of the 
poor prognosis that comes with pancreatic cancer. 
With long-term breast cancer survivors, they have 
time to get angry, time to fight the disease and 
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survive, and then years to raise money and spread 
awareness. However, for pancreatic cancer, you are 
talking about typically a short survival period, which 
is heart-breaking, and people just have the time to 
get their affairs in order. It is just not fair.
Q: I read that you developed a ubiquitous tool in 
DNA analysis. Can you tell me a bit about that? 
Was this tool inspiration for some of your future 
research? 
A: That project actually came from a mistake that 
was written in a lab protocol. I spent months working 
with that protocol before I realized that it was an 
error. It prompted me to ask the question, “Should 
we always accept what is written on a protocol?” 
The answer of course is no, we can always make 
improvements. 
On realizing the error, I decided that it was 
something I could improve upon, and we ended up 
making a substitute for a new and better tool. The 
published paper allowed us to get a patent. Some of 
the students in my lab recently revisited my initial 
project and feel that they can better the technique 
by using a new technology, so we hope that we may 
be able to improve on the tool again.It is because of 
this experience that I often tell my students, “Don’t 
just accept what is on the written page, always 
question whether you can do it better.”
Q: I saw that you presented on CRISPR at Jefferson 
a few years ago. How has the development of this 
technology influenced you in recent years?
A: My lab has already published one paper using 
CRISPR technology, and both Dr. Jordan Winter 
and my lab are on the brink of publishing two more. 
From a research stand point, the technology is 
revolutionary — a phenomenal tool — and Jefferson 
is in the process of establishing a connection with 
Christiana Hospital to create a CRISPR institute.
Whether or not it will have a place in clinical 
practice is yet to be seen. There is a wonderful 
Ted Talk by geneticist Jennifer Doudna that you 
should check out. (https://www.youtube.com/
watch?v=TdBAHexVYzc) It is definitely a very useful 
tool, but it needs some manipulation to apply it to 
the clinical setting.
Q: I saw online that you are involved in multiple 
projects with different institutions both in the 
United States and worldwide. Can you tell me a 
bit about your projects? And your collaboration 
between other national and international hospitals?
A: I think collaboration is great. My lab has 54 
projects in process, and probably over 20 of them 
are collaborations with other institutions. We have 
a lot of collaboration with Israel, and now we also 
have projects with Kansas, Stanford, Columbia, Fox 
Chase, Drexel, and Georgetown. One of the great 
things about the pancreatic cancer community 
is that we are all very collaborative, there is some 
competition (we are all applying for the same 
grants), but the camaraderie is there.
One of my current projects is with Oregon Life 
Sciences in Portland. We are writing a grant to create 
a live bio bank of specimens, so that we can do 
molecular and drug studies on live tumor samples. 
It is a huge project, and something we are all very 
excited about. I am also part of a precision medicine 
endeavor, which is a multi-institutional project. 
I think that my partnership with Dr. Yeo opened a lot 
of doors for me, both nationally and internationally, 
and since my lab’s opening, our work has been 
strong enough that people want to collaborate 
with us. For example, I just returned to the States 
from giving a talk in Manchester, UK as I have a nice 
collaboration there too.
For the most part, people who go into research in 
pancreatic cancer want to make a difference. I think 
that we as researchers realize that success correlates 
to teamwork, communication, and collaboration. If 
you are going to make a difference with this disease 
you cannot work in silo.
CONCERNING PANCREATIC CANCER
Q: What do you think have been the greatest 
recent advances in the field of pancreatic cancer 
medicine and surgery? Do you think there is a 
field-changing advancement on the horizon for 
pancreatic surgery? For cancer as a whole?
A: I think that the way we are starting to manage 
the disease shows that we are getting better at 
treating it. The surgery aspect of it at Jefferson 
is outstanding, and we are also getting better at 
controlling people’s pain. 
There are some recent data that have evaluated 
different ways of treating the disease. For example, 
neoadjuvant vs. adjuvant therapy, or both. Although 
not completely decided on, recent studies have 
indicated that neoadjuvant therapy might be the 
way to go in certain instances.
The personalized side to pancreatic cancer 
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treatment is still in its early stages. I was part of a 
paper that showed that a decent percentage of 
patients have mutations that could potentially 
respond to drugs that are already in circulation as 
treatment for a different disease. There are a lot of 
targeted therapies in the lab that I am excited to 
move to the clinic, but doing a specific clinical trial 
is difficult, especially for the rarer mutations.
I think that our general understanding of the disease 
has been enhanced in recent years through our 
discovery that pancreatic cancer is not just made up 
of tumor epithelial cells, but that there is a tumor 
micro-environment that involves things like stromal 
cells and fibroblasts. So the main question we now 
have is: how do we navigate and target that? 
I think there is hope, and I think that there are going 
to be some major breakthroughs in the next 5 to 10 
years. We keep creeping up in our 5-year survival 
percentages, from 6% a few years ago to 9% now. 
We are better at managing patients clinically, and I 
think that will dove tail when we start being able to 
use personalized treatments and expand our drug 
arsenal.
Q: In your view, are there any current projects in the 
field that may dramatically change the detection or 
treatment of the disease in the near future?
A: There are a few projects that are really exciting. 
There is a drug called pyrvinium pamoate, which 
is currently a treatment for pinworms, which can 
target a molecule that is very pro-oncogenic. We 
think that it could be a good sensitizer for current 
drugs or even act as a monotherapy for treatment 
for pancreatic cancer. We are in the process of 
completing the pharmacokinetic studies for this 
project, and we hope to do a clinical trial next year.
Q: I saw on your Twitter feed that you attended 
TRIP18, the first Israel Symposium on Pancreatic 
Cancer. Do you find the treatment of pancreatic 
cancer to be an international field, and if so, are 
there particular groups internationally that have 
influenced your research projects?
A: My collaborator in Israel, Talia Golan, (Sheba 
Medical Center in Tel Aviv) has a very unique 
population. She has the highest volume of Ashkenazi 
Jews with pancreatic cancer who have the BRCA2 
mutation. She has developed cell lines from these 
patients, which she sends over to me so that we can 
use them in our lab.
We also have a partnership with Hebrew University 
to study a biochemical RNA binding protein, and of 
course our affiliation with Manchester, UK.
OFF THE WALL QUESTIONS
Q: What was your first published paper on?
A: I am really aging myself here! But it was on the 
cloning of a gene. This was before the internet, 
in the early to mid-90s. My project focused on 
cloning this gene and studying its properties. One 
of the reasons I am now currently studying the HuR 
protein is because it is linked to that gene.
Q: If you could go back in time and tackle your 
past projects in a different way, what would you 
change?
A: This is something that I often ask myself. I would 
say that I tend to be very incremental in my work, 
and sometimes I wonder whether thinking bigger is 
a good thing. However, there is also a financial cost 
to thinking too big too soon, because sometimes 
it is the journey that allows you to discover the big 
picture. 
The pyrvinium pamoate project has taken about 
a decade to reach the clinical trial phase because 
we got there through a series of steps, and I do not 
know if we would have gotten there if we had not 
followed that path. In a way, you have to earn those 
big ideas and breakthroughs. It is always about the 
journey.
Q: Do you still play the drums outside of work as a 
release to help you prevent burn out? 
A: I used to use the drums as an outlet, but now 
with running a lab and having a seven-month-old 
at home, it makes it very difficult. When I first came 
to Jefferson, I played in a band with the medical 
students. I still hold my drum set and want to play, 
but for now I use that extra energy to go and listen 
to live music.
Q: What other things do you enjoy doing in your 
spare time?
A: Traveling with my family. My wife and I, and our 
baby, have been to Israel, the UK, and Italy this year. 
We were able to link to some scientific conferences. 
We are very fortunate that the little one travels well. 
And then of course, exercise and listening to live 
music. I love to play basketball. A group of the guys 
and I will get up and play basketball at 6am. It keeps 
me young! I also love running and being outdoors. 
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Surgeon-Led Imaging Review for Patients with 
Periampullary Disease: An Important Aspect of 
the Preoperative Consultation1
At surgical consultations, an abundance of radiologic 
studies often accompany a patient. Despite being 
common practice during patient visits involving 
the discussion of upcoming procedures, there is a 
paucity of literature specifically investigating the 
benefit of incorporating the actual viewing of their 
own images by the patient. The possible benefits of 
utilizing imaging as a means of educating patients 
include facilitation of a better understanding of 
one’s diagnosis and more active participation of 
the patient in their care plan. This article is the first 
to examine these perceived benefits to educate 
and include patients in their care plan. In this 
study, patients with pancreaticobiliary surgical 
consultations were surveyed before and after their 
appointments, during which a surgeon scrolled 
through CT and/or MRI scans with the patient 
and family. Using a five point Likert scale, patients 
reported their perceived importance of viewing 
their imaging studies and understanding their 
medical conditions. Of 51 patients surveyed, 78% 
reported they had not previously seen their imaging, 
and 55% of patients thought it was important for 
them to do so. On average, surgeons spent 2.7 
minutes reviewing imaging studies with patients 
and family. On the post visit survey, 90% and 86% 
of patients, respectively, responded positively 
to better understanding their disease and their 
planned operation having seen the imaging studies. 
After these appointments, almost all patients felt 
that the imaging review with their surgeons was 
valuable and enhanced their understanding. Based 
on the findings of this study, the authors argued 
that surgeons should incorporate imaging reviews 
into their patient encounters. 
Leakage of an Invagination Pancreatico-
jejunostomy May Have an Influence on Mortality2
Whipple procedures are currently the gold standard 
for treating pancreatic ductal adenocarcinoma 
(PDA). The most common complication of this 
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The Journal of Pancreatic Cancer
by: Harold I. Salmons, Class of 2020
In the realm of oncology, cancer of the exocrine pancreas is an especially lethal malignancy. Annually, exocrine pancreatic 
cancer is the third leading cause of cancer death in the United States and the eighth leading cause of cancer death worldwide. As 
the organ itself is embedded between key vasculature and digestive and biliary organs, pancreatic cancer is a very challenging 
disease to treat. At the moment, surgical resection is the cornerstone of the only curative option for exocrine pancreatic 
cancer. Unfortunately, the disease classically presents late, and only a minority of patients qualify for surgery at the time of 
diagnosis. Research is therefore a key measure in trying to address this disease and hone its cures. 
Efforts are underway worldwide to understand the molecular and clinical manifestations of pancreatic cancer, and further refine 
its medico-surgical treatment. The Journal of Pancreatic Cancer (JPC) is the only peer-reviewed journal focused exclusively 
on pancreatic cancer. Led by Editor in Chief, Samuel D. Gross Professor and Chair of Surgery at Thomas Jefferson University, 
Charles J. Yeo, MD, this international journal offers open-access, peer-reviewed articles covering the clinical, translational, 
and basic science of malignancies of the pancreas and the peripancreatic region. The JPC is a terrific resource to surgical 
oncologists, pancreatologists, gastroenterologists, radiation oncologists, medical oncologists, endocrinologists, pathologists, 
palliative care specialists, epidemiologists, immunologists, and cancer researchers investigating problems and treatments 
for pancreatic cancer. From molecular genetics to surgery, this journal offers the most broad and thorough investigation of 
pancreatic cancer-related research topics. 
The Jefferson Pancreas, Biliary and Related Cancer Center serves as a shining example of what can be accomplished in the 
field of pancreatic cancer research. The team of surgeons, oncologists, gastroenterologists, and researchers have emerged 
as pioneers in the field of pancreatic malignancies, both through their research efforts and their recognition of key surgical 
findings that are uncovered during their operations. This article intends to highlight some of these achievements by casting a 
light on a few of Jefferson’s more recent impactful publications in the Journal of Pancreatic Cancer. 
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procedure is a postoperative pancreatic fistula, 
which is a leakage of amylase-rich fluid from the 
site of the pancreaticojejunostomy (PJ). Among 
the three anastomoses performed for pancreatic 
reconstruction, the PJ is generally considered 
the “Achilles’ heel” of the procedure, due to its 
significant importance in patient recovery. There 
is no consensus regarding the most effective form 
of PJ following a Whipple procedure. To mitigate 
the risks of fistula, many techniques have been 
studied: alternative anastomotic techniques, the 
use and management of intraperitoneal drains, 
fibrin glue, and pharmacological agents, but none 
have proven definitively effective. The two standard 
PJ anastomotic approaches are invagination PJ 
(IPJ) and duct-to mucosa pancreaticojejunostomy 
(DmPJ). In this study, Dr. Harish Lavu’s team aimed 
to retrospectively compare morbidity and mortality 
between IPJ and DmPJ using the multi-institutional 
American College of Surgeons-National Surgical 
Quality Improvement Program (ACS-NSQIP) 
Pancreatectomy Demonstration Project. Patients 
who received a DmPJ or IPJ differed with respect 
to preoperative and intraoperative variables, hence 
the groups were not strictly identical. The authors 
concluded that IPJ leaks may have a greater 
influence on mortality than leaks in DmPJs, and that 
further study is warranted.  
Pancreatic Mass in a Patient with a History of 
Resected Renal Cell Carcinoma and Resected 
Adenocarcinoma of the Ampulla of Vater: A Case 
Report3
Metastasis to the pancreas from a different primary 
cancer site of origin is rare. This report presents a 
fascinating case in which a patient with past renal 
cell carcinoma (RCC) status post-left nephrectomy 
and ampullary adenocarcinoma status post-
Whipple had a metastasis to his remnant pancreas. 
This patient underwent resection via completion 
pancreatectomy, which revealed pathology 
consistent with metastatic RCC. This paper 
discusses the importance of timing in regard to 
properly identifying a primary versus metastatic 
tumor. Metastasis of RCC to the pancreas often 
presents many years after a primary resection. 
Conversely, recurrent PDA often presents within 
5 years of resection. Additionally, if one resects 
the RCC tumor, outcomes are often better than if 
one resects a recurrent PDA. The authors of this 
paper recommend resecting suspected isolated 
pancreatic RCC metastases due to these known 
favorable outcomes, however this is still a highly 
debated topic.  
Perioperative Management of Factor V Leiden and 
Pancreatic Adenocarcinoma4
The perioperative management of a patient with 
Factor V Leiden has been infrequently reported. 
Further, before this article, there were no reports of 
the management of this disorder during pancreatic 
surgery. This report was of a 74-year-old woman 
with known Factor V Leiden disorder (which causes 
increased clot formation), who came to her primary 
doctor with pruritis, tea-colored urine, pale stools, 
and jaundice for a week. She had a CT-confirmed mass 
of her pancreas and underwent a pylorus-preserving 
Whipple procedure. She did not have immediate 
perioperative embolic or thrombotic phenomena. 
Despite being a common hypercoagulable disease, 
this was one of the first case reports in the literature 
describing the management of a patient with Factor 
V Leiden disease undergoing pancreatic cancer 
surgery. The successful management of patients 
with hypercoagulable states undergoing surgery 
involves anticoagulation medications, such as low 
molecular weight heparin or a heparin to warfarin 
bridge, for a minimum of 3 months. However, the 
authors discuss the challenges of avoiding bleeding 
events in surgery patients on anticoagulants, and 
consequently these risks must be considered while 
managing these patients.
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Q: Bob, you clearly developed a strong relationship 
with the physicians at Jefferson who took care 
of Mary. Can you describe what brought you to 
Jefferson in the first place and how you met Dr. 
Lavu?
BH: We went to Jefferson based on the 
recommendation of our PCP, largely because 
of Dr. Charles J. Yeo’s reputation. We made an 
appointment as soon as we could after the initial 
diagnosis. Interestingly enough, when Mary went 
down [for] a procedure to put a stent in, because 
she was having a blockage, we had assumed we 
had made the appointment with Dr. Yeo, but then 
Dr. Lavu came into Mary’s room while she was 
recovering from the procedure. And at that point 
there was an instant connection. Dr. Lavu had 
a wonderful bedside manner and seemed very 
intelligent, and had a very calming demeaner. 
Over the course of Mary’s treatment at Jefferson, 
the two of them really developed a patient doctor 
relationship, they befriended one another. 
Q: Dr. Lavu, what do you remember about Mary 
from that first encounter?
HL: I remember Mary as just an unforgettable type 
of person. Mary was a high energy person, a person 
who just has a thousand-watt smile, that kind of a 
person. We hit it off right away. 
Q: Bob, do you think that relationship played a big 
role in how your family was able to deal with the 
course of the disease and the hospital visits?
BH: Definitely. Really all of the physicians down 
there, including the nursing team, but Dr. Lavu 
mainly for the surgical management and then on 
the medical side Dr. Edith Mitchell, who again had 
a wonderful bedside manner with Mary. Mary was 
always a pleasant person, easy to get along with, 
and people just gravitated toward her, and she just 
befriended Dr. Mitchell too and they became friends. 
We had many visits with her, a lot of it was just, not 
only the medical part, but on the personal side too. 
I think it helps to know you’re in good hands, and 
there’s a compassion there that’s real. It’s not a 
forced compassion. The way I viewed it, and I know 
Mary viewed it, it was real compassion for patients, 
real compassion for Mary, and when I go to these 
symposiums and am sitting around the table there 
and talking to patients or caretakers, they all have 
the same message: not only great clinical care, but 
the compassion they feel. And I think that is helpful 
in dealing with the diagnosis.
Q: How has your relationship with each other 
changed over the years?
BH: It’s interesting, Mary had the connection, not 
that Dr. Lavu and I didn’t have a connection, but we 
weren’t as close, so to speak. I think that once Mary 
passed, not only was it tough on me, but I think 
on Dr. Lavu, it really moved him, and it was tough 
on him because he really wanted Mary to survive 
longer than she did. I know that the doctors have to 
be professional, but you’re human too, and I think 
by establishing the fund, I was able to continue the 
relationship with Dr. Lavu, where we’ll touch base 
periodically on a friendship basis, and partly also 
on a professional basis, as far as getting updates 
on where things are going with pancreatic cancer 
research. So I sort of stepped in the shoes of Mary 
a little bit, not so much because that was a special 
relationship they had, but I call Dr. Lavu a friend and 
I think likewise he probably feels the same about 
me. 
HL: We’re very close, because we shared an 
experience. Obviously, Bob was there every step 
of the way for his wife. We developed a closeness 
The Mary Halinski Pancreatic Cancer Research Fund and its 
Impact on Pancreatic Cancer Research at Jefferson
by: Samantha L. Savitch, Class of 2021
I had the pleasure of speaking with Bob Halinski, founder of the Mary Halinski Pancreatic Cancer Research Fund, and Dr. 
Harish Lavu to discuss the state of pancreatic cancer research. Bob founded the Halinski Fund in honor of his late wife, Mary, 
who passed away from pancreatic cancer in 2013. Along with his daughter, Stephanie, and son, Luke, Bob hosts a fundraiser 
every year called “Ride and Renew” to raise money for research endeavors at Jefferson and educate the community about 
this important disease. Bob is the recipient of the 2018 Community Impact Award for his work as a fundraiser and advocate.
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through that process that lasts to this day.
Q: While Mary was going through treatment, were 
there any experimental options that were offered 
to her?
BH: There were some clinical trials that were made 
available. Mary was in a couple different ones, but 
not anything groundbreaking. One that Mary didn’t 
do, and I think there was a little bit of disappointment 
on Dr. Lavu’s side and some of the researchers there, 
was a vaccine trial that was going on. Mary was a 
clinical person, she worked at a pharmaceutical 
company, she had a science background, so she 
understood all of that. I’m a finance person so it 
was always difficult for me. But for that one clinical 
trial, we both did our own independent analysis of 
it, and came back with the conclusion that we didn’t 
think it was worthwhile. There was no regret on the 
decision. You make the decision based on what you 
have. We never second guessed that. We just trusted 
our judgment. Sometimes you have to face what’s 
staring in front of you.
Q: Tell me about Mary’s background. I hear she 
was a big player in patient advocacy. What drove 
her to be so involved in the community?
BH: Part of it is just her personality, it’s just her 
character and her makeup. She was just a giving 
person. She always looked to help others. She would 
help not only to take care of me and my two children, 
and her mom, but she was just a giving person across 
the board. My son had a lot of health issues when he 
contracted undiagnosed Lyme disease, and he had a 
lot of pretty significant adverse manifestations from 
that, and she took it upon herself to be an advocate 
for patients. She was very good politically – reaching 
out to federal legislators, state senators, and trying 
to get legislation that could direct funding toward 
Lyme disease research. She just liked helping people. 
Every day of her life she liked to help people. 
Q: How did the idea for the Mary Halinski Fund 
come to be? What did it entail to put it in place?
BH: Mary really appreciated what Jefferson was 
doing for her, and the care that was being provided 
throughout her whole treatment, so she made 
donations to the existing Jefferson pancreatic 
cancer research fund. After she passed away, [I 
thought about] her whole legacy of giving and 
being an advocate for patients, for people, and 
helping people across the board. Laura Goldstein 
[of Jefferson’s philanthropy department] had 
reached out to Mary thanking her for the donation, 
so I sent a note to Laura, and said, “Hey, if I want 
to do something in Mary’s name, what could I do?” 
The idea of a research fund in her name just seemed 
like the perfect fit, for me and for Mary. It kept her 
legacy of giving alive. She loved science, she loved 
learning, she loved helping people. And I thought if I 
start an endowed fund in her name, what better way 
to honor her legacy? If research advances are made 
by the Jefferson research team, and it’s published 
and they make advances at some point, I would 
love Mary’s name to be part of that. And that’s why 
I thought that was the way to go. And I felt really 
good about it, and it helped me. When somebody 
you love dearly passes away, this is a way to have 
some positive come out of, and it accomplished 
that. It helped me in the healing process to try to 
move forward, and the continuation of the fund has 
been helpful. And the thing that’s amazing is there’s 
a lot of things in this world that don’t go right, but 
there’s a lot of goodness in this world too, and when 
you establish a fund like this, it’s just nice because 
people step up to the plate. 
Q: What does the fund look like now? What are the 
main goals and what types of events are associated 
with it?
BH: Our fund is not the largest fund in the world, but 
it’s a start. I think part of the fund is to use it to seed 
research. To get the multimillion dollar grants, you 
have to have a testing ground to prove to whoever is 
providing that grant, whether it’s a private foundation 
or the government, people want to see, “Is this going 
to work?” That’s really what our money is being used 
for. The main fundraiser every year, which we started 
a couple years ago, is called “Ride and Renew”. It’s 
a one-day event, and it’s a combination of indoor 
cycling, spin classes, and yoga classes. I’ve become 
an avid cyclist and yoga is great for me to improve 
my health and has helped me move forward after 
Mary’s passing. My daughter also enjoys cycling and 
recently became a certified licensed yoga instructor, 
so we just found that this would be the right fit for us 
to have some forum to raise money, help physically 
and mentally too, and it gave us a venue to get the 
word out. We just want to get Mary’s name out there 
and keep her name alive, but also let people know 
about pancreatic cancer. As you know, it’s so lethal. 
All cancers are bad, but this one seems particularly 
lethal. I don’t think people know that, and when they 
hear the statistics, it touches them. So that’s what 
we do, and this will be our third year now. It’s been 
received pretty nicely, and we’re happy about it. 
This year’s “Ride and Renew” will be held on Sunday, 
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November 18th.  
Q: What has your involvement in the pancreatic 
sphere been outside of the fund?
BH: I just support the other organizations. I support 
their events. I try to show up to those, any one that’s 
local that I can drive to I’ll usually go and support 
people. Everybody just sticks together on that. I’m 
not active in any other way than participating and 
making contributions to those funds. I like the money 
to go to Jefferson, but these other organizations do 
wonderful things too. 
Q: You’re being given the Community Impact Award 
at this year’s Pancreatic Cancer Symposium. Can 
you tell me a bit about when you found out about 
that award and what it means to you?
BH: I received a letter from Dr. Yeo directly telling me 
about this inaugural award and that they’d like me to 
be the recipient and outlining why. My first reaction 
was, “You guys don’t need to do this.” I appreciate 
the award, but I just want to do what I’m doing and 
help. But I am grateful for the acknowledgement, 
because I do try to make an impact. But it’s about 
Mary and it’s her award and her fund, and it just 
needs to be about her. The thing I like about it is, if in 
the course of getting this award and telling my story, 
maybe it can help people who have gone through a 
pancreatic cancer diagnosis move forward. Maybe 
people will think, “This guy encountered this and 
he’s doing pretty well and trying to make a positive 
out of a negative.” And that actually makes me feel 
good about this.
Q: Dr. Lavu, how has Bob’s work influenced the 
community and how does he embody this award? 
HL: The thing that’s been really impressive is that 
Bob went through this experience with Mary, [and] 
he could have left it with that and just let it be. But 
he decided he wanted to do something, along with 
his daughter, Stephanie, and his son, Luke. And not 
only have they supported research and donated 
their own money, but they’ve hosted a fundraiser 
which serves the purpose of raising money and 
getting education out there to the community. 
And to me that’s so amazing. That’s so critically 
important, because people out there don’t know a 
lot about pancreatic cancer. I’ve been able to attend 
a number of the events that Bob and Stephanie have 
put on, and they’ve been great. And then Bob has 
been supportive of other families and other groups 
who have put on their events. We’ve met at other 
people’s events, he’s been supportive of them. He’s 
one of these glue people, I think, a person who 
brings other people together, that’s how I think of 
Bob. I just think it’s really fitting that he’s getting this 
award. 
Q: What do you see as the biggest impact that the 
fund has had on the pancreatic cancer sphere?
BH: Just in general, when I hear about some of the 
small advances that they’re making in findings, I just 
feel really good. I know the research takes a while 
to run its course to really make a difference, but 
what I like is when I hear the little advances they 
discovered in six months and how they plan to use 
it, that’s what excites me. I get reenergized. I sit 
down with the researchers every six months, and 
when I leave there, I think, “Okay we’re making a 
difference here.” You publish this, other researchers 
will look at it, and they will say, “I like that idea let’s 
run with this coupled with something else.” That’s 
how I view the fund. 
HL: It’s been tremendous helping us continue our 
pancreatic cancer research here. The things we do 
clinically, we work together with our basic scientists 
such as Dr. Jonathan Brody. And the Halinski Fund 
covers the funding for young researchers to carry 
on this work and to train the next generation of 
researchers and basic scientists. Ultimately, the next 
great leap forward will come from a laboratory. And 
we all know that, even as clinicians as we take care 
of patients every day. So for us, it’s very important to 
have a fund like that.
Q: Dr. Lavu, what does the field of pancreatic 
cancer research look like right now?
HL: Pancreatic cancer is being attacked on 
so many different fronts, whether it’s early 
detection strategies, whether it’s new targeted 
therapies, whether its understanding how to use 
chemotherapy more effectively. In the surgical field, 
in the last ten or fifteen years, we’ve become much 
more aggressive in the kind of surgeries that are 
being done. We’re doing more minimally invasive 
surgery. We understand how important it is to get 
the patients through recovery so they can get on to 
adjuvant therapy. And that has improved lightyears 
in terms of postoperative and preoperative care. 
Ultimately, there will be breakthrough medications 
that will be developed that will put pancreatic 
cancer more on a par with breast cancer or colon 
cancer, which are cancers that are treated in 
very similar ways to pancreatic cancer: surgical 
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resection, chemotherapy, sometimes radiation 
therapy. But the main difference is that, for those 
cancers, the chemotherapy is incredibly effective, 
and for pancreatic cancer we’re not there yet.
Q: What is a reasonable goal for five years from 
now?
HL: We know that the incidence of pancreatic 
cancer is rising. By 2020 it will be the second 
leading cause of cancer death in the US. And that 
is being driven by demographic forces: the aging 
population, aging smokers, and then the crisis of 
obesity and metabolic syndrome. All of these are 
driving pancreatic cancer development. When I 
first had the inkling that I might even be interested 
in this field, 18 years ago, the number quoted in 
research papers for five-year survival was very low, 
but it has been slowly inching up since. In five years, 
my hope is we can double the survival rate that we 
see today, because the pace of knowledge, the pace 
of scientific research is accelerating. I think that’s 
a reasonable and realistic goal. In fact, I want it to 
be better. I hope it can be even better. I hope I’m 
underselling it.
Q: Are there any recent findings or research on the 
horizon that could prevent stories like Mary’s from 
happening?
HL: There was literally a breakthrough in our 
understanding of adjuvant therapy for pancreatic 
cancer just three months ago. A large-scale, 
multicenter trial showed that combination 
chemotherapy, that people thought was too 
aggressive for patients after surgery for pancreatic 
cancer, it turned out it did a fantastic job in 
preventing recurrences and prolonging people’s 
lives. That was a huge, huge breakthrough. And it 
changed the standard of care almost overnight. 
The patients we see today are being advised to 
get a combination chemotherapy that they were 
not advised to get in May of this year. That’s how 
quickly it’s changed. And that’s why I say the pace 
of development is accelerating in our society, for 
everything, and I think that it will serve to help 
pancreatic cancer care.
Q: I read that the Halinski Fund contributed to the 
Jefferson study looking at HuR. How influential 
has the Halinski fund been on pancreatic cancer 
research at Jefferson?
HL: I think [the fund] has been a pillar of helping 
support pancreatic cancer research here at 
Jefferson. And the HuR story is one of the 
important molecular themes in pancreatic cancer 
development. Dr. Brody’s lab is amongst the world’s 
leaders in understanding HuR. I just think it’s very 
exciting, and I know that the researchers who are 
being funded to be able to do this work through the 
generosity of the Halinski fund, these are your next 
generation of GI cancer researchers. So I just think 
it’s an immeasurable impact.
Q: What do you each see as the role of health care 
professionals in these kinds of funds?
BH: Awareness. Physicians, your focus, and rightly 
so, is on the clinical aspects of it, and trying to heal 
the patient or make their quality of life better. That’s 
why you go to medical school, to treat patients. But 
I think that for a fund like this, the physician’s role 
is just to let patients know that there are funds like 
this, that are helpful for your ability to give back, 
or make a positive difference. So don’t be averse 
to it. People say that’s the development people’s 
job to raise money and awareness. But I think the 
physicians need to collaborate and work and I think 
Jefferson does a good job of that, you know the 
balance between the need to get funds for research 
and help as best they can. 
HL: I think that the bottom line is I’m in the field of 
pancreatic cancer care as a doctor, as a surgeon, as 
a researcher. And philanthropy is one of the ways 
that one advances the field. If you look at funding 
for cancer research from the NIH, pancreatic cancer 
is tremendously underfunded. The NIH and the NCI 
have not caught up with the proper funding levels 
to look for the breakthroughs that we have gotten 
for breast cancer, for colon cancer, for melanoma. 
There are amazing stories out there for some of 
these other types of cancers, and most of those 
stories started in basic science labs. So philanthropy 
is one of the ways that pancreatic cancer research 
is being conducted these days. My role is to get that 
message across. 
Q: Dr. Lavu, as a healthcare provider, how would 
you bring up philanthropy to a patient, student, or 
other person in the community?
HL: I think that different doctors do it in different 
ways and have different comfort levels. Certain 
people have a natural ability to bring up things like 
that. I do think it’s important to recognize though 
that when you’re caring for a patient, for a family, 
it’s really critical that you have a close bond and 
it’s all related to medical care. The philanthropy 
picture is something that comes up later on, down 
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the road, when your direct care is mostly finished 
at that point. But oftentimes patients or families will 
say, “What can we do to help?” And there is a lot 
of research that shows that people who have been 
through a medical condition or family members, 
there’s a feeling of helplessness. Because you’ve 
gone through this thing, and maybe you’ve made it 
out the other side, but you feel like, “What can I do 
to help other people?” And there’s a lot of research 
that says that being involved with philanthropy is 
tremendously healing for patients that undergo 
these traumatic medical experiences of having 
illnesses. So for the people who are interested in 
that way, I enjoy chatting with them about it. 
Q: What would you say to people who are interested 
in their own funds or donating to funds? What is 
the process like?
BH: If you’re thinking or inclined to be doing 
something, really think about it seriously, because 
you’re going to feel good about it. I always tell folks 
to act upon that, whether its setting up a fund in a 
loved one’s name, that’s great, but Jefferson has a 
wonderful existing fund too. And it really does make 
a difference. Every dollar counts. Jefferson is really 
good stewards of that money, and they are using 
it essentially 100% for research. It’s not going to 
overhead or anything else. And the process is very 
simple, but can be pretty customized to what your 
needs and desires are. The development team is just 
really nice to work with.
HL: We have a liaison between our surgery 
department and the philanthropy office at 
Jefferson. They work very closely with us because 
they’re involved in helping run a lot of pancreatic 
cancer awareness events and things of that nature. 
So if a patient or family member is interested, I’ll just 
serve as the person who puts two people together. 
Q: Is there anything else you want people to know 
about Mary or the fund?
BH: Mary was just a special person. She just gave so 
much of her time for others. She volunteered, she 
was a very strong person of faith, and she relied on 
that to help her deal with everything. She donated 
a lot of time to her church, and she visited nursing 
homes and the elderly and prayed with them as part 
of the Catholic faith. She donated her time to going 
down to the soup kitchen to feed the homeless. 
She just helped people all the time. That’s who she 
was. She was a selfless person, but very positive too. 
She’d make friends instantly. She went to jury duty 
and she got there and had all these friends. And I 
was like, “How did you make friends with jurors so 
quickly?” But that’s the person she was. She just 
connected with people. She was selfless and giving 
and had a strong faith in God and it was wonderful 
to see that. And it’s helped me and motivated me 
in lots of ways. And that’s why this fund is a way to 
continue to honor her. She loved to give to people 
and give herself, and this is the perfect thing for her. 
Bob and Mary Halinski in August of 2011
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THE GIBBON SURGICAL SOCIETY
The John H. Gibbon, Jr. Surgical Society (GSS) at Sidney 
Kimmel Medical College (SKMC) at Thomas Jefferson 
University is a unique student interest group that has 
been working hard to increase interest in the field of 
surgery among medical students for the last 37 years. 
The society has over 400 total active members on a year 
to year basis, spread across the four-year curriculum. 
The GSS increases exposure and interest to the surgical 
field through a unique blend of episodic and longitudinal 
programming that helps bring together students, 
residents, and faculty in an educational setting. 
The crux of the GSS approach to bolstering medical 
student interest is early exposure. Over the years, the GSS 
has run many programs specifically targeted at students 
in the pre-clinical curriculum to increase surgical 
exposure. Potentially the most influential program is 
Surgery at Night, which provides an opportunity for 
students to spend an overnight shift with a surgical 
resident and intern early in their medical school career; 
there are typically over 200 such overnight stays by 
students in an academic year. Students frequently have 
the opportunity to scrub in on emergent cases and are 
often instructed in suturing small incisions at the end of 
cases. Another excellent opportunity for students is the 
Organ Procurement Program, in which all students who 
receive the necessary training are signed up for a lottery 
that allows them to travel and scrub in with the organ 
procurement team. The most innovative program that 
has been started by the GSS is the SCALPELS program, 
in which faculty members and upperclassmen plan a 
longitudinal surgical curriculum that runs concurrently 
with the pre-clinical curriculum, and offers surgery-
specific lecture topics and skill sessions relevant to the 
underclassmen’s studies. 
There are also events that are available to all students. 
The GSS runs a quarterly journal club, which is led by a 
surgeon at Jefferson in the field that is currently being 
studied by the second-year medical students; typically, 
one “classic” article from the literature is discussed 
and contrasted with a contemporary article. The basic 
anatomy and physiology are presented by a first- and 
second-year medical student, and the findings of the 
papers are reviewed by a third-year medical student. 
Many surgeons take this time to not only educate the 
students in critical review of the findings of papers, 
but also the underlying statistics that were used. The 
Philadelphia Surgical Symposium is the GSS’s signature 
event and is run in the spring of each year. Students 
from all medical schools in the Philadelphia region (six 
schools in total) are invited, and it is intended to be an 
informative opportunity for medical students interested 
in surgery. There is an associated regional medical 
student research poster session and competition 
during the event, complemented by presentations from 
a faculty member from each school, ranging in topics 
from clinical experiences, to advocating for a particular 
field of surgery, to hot topics in research. The event 
concludes with a two-hour networking session, either 
on site or at a nearby venue. 
The GSS was presented at the AAMC’s Learn, Serve, Lead 
2017 conference as a model for an effective medical 
student interest group. This journal, the GSR, is written, 
compiled, and curated by SKMC students through the 
invaluable help and planning of the GSS members, and 
stands not only as a testament to the involvement and 
hard work of the GSS, but also of the student body as a 
whole. 
-Tyler M. Bauer, Class of 2020 
Senior Editor
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Dr. Charles J. Yeo was born in East Orange, New Jersey, 
and attended Spring Valley Senior High School in 
Spring Valley, New York. He received his undergraduate 
degree from Princeton University in 1975, summa cum 
laude, with an A.B. in Biochemistry. Dr. Yeo graduated 
in 1979 from the Johns Hopkins University School of 
Medicine, being awarded the Upjohn Achievement 
Award, and was elected to Alpha Omega Alpha and Phi 
Beta Kappa. He went on to complete his residency in 
General Surgery and a fellowship in advanced GI and 
vascular surgery at the Johns Hopkins Hospital.  
Dr. Yeo joined the faculty of the Johns Hopkins 
University as an Instructor and Assistant Chief of 
Service in the Department of Surgery in 1985, and 
rose to the rank of Professor of Surgery in 1996.  Dr. 
Yeo directed the Pancreatic Cancer Interdisciplinary 
Working Group at Johns Hopkins and served as 
the Surgical Clerkship Coordinator and Surgical 
Curriculum Consultant. In 2001, Dr. Yeo received the 
Alumni Association Excellence in Teaching Award from 
the Johns Hopkins University School of Medicine.  In 
2002, Dr. Yeo was named to an endowed chair at Johns 
Hopkins, becoming the inaugural John L. Cameron, 
MD Professor for Alimentary Tract Diseases.
On October 1, 2005 Dr. Yeo was named the 8th Samuel 
D. Gross Professor of Surgery, and he assumed the 
chairmanship of the Department of Surgery at Sidney 
Kimmel Medical College at Thomas Jefferson University 
in Philadelphia, Pennsylvania.  He currently serves on 
the Board of Trustees of Thomas Jefferson University 
Hospital.
Dr. Yeo’s academic accomplishments include being 
Editor-in-chief of  Shackelford’s Surgery of the 
Alimentary Tract, 8th Edition, being an Associate Editor 
of  Advances in Surgery  and past Co-Editor-in-Chief 
of the Journal of Gastrointestinal Surgery, and serving 
on the editorial boards of  Langenbeck’s Archives of 
Surgery, Surgery, and Annals of Surgery. He is the author 
of over 550 peer-reviewed scientific papers, numerous 
abstracts, over 105 book chapters, and 24 books and 
monographs. 
Dr. Yeo’s primary interests and research have been 
in the field of alimentary tract surgery, focusing on 
hepatopancreaticobiliary surgery - the evaluation of 
patients with pancreatic, biliary, and related cancer, and 
the management of patients with unusual pancreatic 
neoplasms, as well as acute  and chronic pancreatitis. 
He travels nationally and internationally teaching and 
lecturing on the treatment of benign and malignant 
pancreatic diseases and has personally performed 
over 1550 Whipple operations. 
CHARLES J. YEO, MD, FACS
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To learn more about supporting pancreatic cancer research or clinical care 
at Thomas Jefferson University Hospital, contact Kelly Austin, Director of 
Development, at 215-955-6383 or Kelly.Austin@jefferson.edu. 
